MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
1.250
-0.010
-0.80%
Opening 09:57 05/12 EDT
OPEN
1.270
PREV CLOSE
1.260
HIGH
1.270
LOW
1.180
VOLUME
8.26K
TURNOVER
--
52 WEEK HIGH
4.400
52 WEEK LOW
0.8500
MARKET CAP
40.22M
P/E (TTM)
-0.7548
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKTX last week (0505-0509)?
Weekly Report · 4h ago
Weekly Report: what happened at AKTX last week (0428-0502)?
Weekly Report · 05/05 09:56
Akari Therapeutics appoints Kubik as Head of Business Oncology
TipRanks · 05/01 13:09
AKARI THERAPEUTICS APPOINTS MARK F. KUBIK AS HEAD OF BUSINESS DEVELOPMENT - ONCOLOGY
Reuters · 05/01 12:45
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/29 21:05
Weekly Report: what happened at AKTX last week (0421-0425)?
Weekly Report · 04/28 10:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/22 21:05
Akari Therapeutics releases video from newly appointed CEO Gaslightwala
TipRanks · 04/22 13:11
More
About AKTX
More
Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.
Recently
Symbol
Price
%Change

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.